473923-97-6

Usage

Chemical Properties

white powder

InChI:InChI=1/C7H4ClNO/c8-6-1-5(4-9)2-7(10)3-6/h1-3,10H

Upstream product

• 473923-96-5 3-chloro-5-methoxybenzonitrile 
• 1213790-87-4 3-chloro-5-((4-methoxybenzyl)oxy)benzonitrile 
• 766-84-7 3-chloro-benzonitrile 
• 6575-00-4 3,5-dichlorobenzonitrile 

Downstream Products

• 473920-64-8 3-[(3, 5-dimethyl-1H-pyrazol-4-yl)oxy]-5-chlorobenzonitrile 
• 473923-68-1 3-(1-acetyl-2-oxopropoxy)-5-chlorobenzonitrile 
• 867366-95-8 C₁₄H₆BrClFNO₂ 
• 1155847-25-8 3-chloro-5-[(3-chloro-2,5,6-trifluoropyridin-4-yl)oxy]benzonitrile 
• 1155847-15-6 3-chloro-5-[(2,6-difluoropyridin-4-yl)oxy]benzonitrile 
• 1155846-91-5 3-chloro-5-[(5-chloro-3,6-difluoropyridin-2-yl)oxy]benzonitrile 
• 1210835-26-9 C₁₃H₈ClN₃O₄ 
• 1210835-14-5 C₁₉H₁₂ClN₃O₄ 
• 1210835-59-8 3-chloro-5-(2,3,6-trifluoropyridin-4-yloxy)benzonitrile 
• 1210835-92-9 C₁₄H₉BrClN₃O₄ 
• 1210836-14-8 C₁₉H₁₁BrClN₃O₄ 
• 473924-02-6 C₁₄H₁₄ClNO₃ 
• 770719-10-3 [3-(3-chloro-5-cyanophenoxy)-2-fluoro-4-nitrophenyl]acetic acid ethyl ester 
• 770719-09-0 3-chloro-5-[(2,3-difluoro-6-nitrophenyl)oxy]benzonitrile 

Relevant academic research and scientific papers

Iridium-Catalyzed Silylation of C-H Bonds in Unactivated Arenes: A Sterically Encumbered Phenanthroline Ligand Accelerates Catalysis

We report a new system for the silylation of aryl C-H bonds. The combination of [Ir(cod)(OMe)]2 and 2,9-Me2-phenanthroline (2,9-Me2-phen) catalyzes the silylation of arenes at lower temperatures and with faster rates than

A synthesis of 3,5-disubstituted phenols

Robust and scalable syntheses of some synthetically useful 3,5- disubstituted phenols are presented. The process involves the selective displacement of a halogen by nucleophilic aromatic substitution using a preformed mixture of potassium tert-butoxide and p-methoxybenzyl alcohol (PMB-OH), followed by deprotection of the PMB ether with acid in the presence of 1,3-dimethoxybenzene. These processes have been demonstrated on kilogramscale, providing crystalline phenols in good yield and high purity.

HETEROCYCLIC ANTIVIRAL COMPOUNDS

Compounds of formula I, wherein R1, R2, R3, X1, X2 and Ar, are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.

NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

Compounds of formula (I), wherein R1, X1, X2 and A, are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula (I) useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.

CHEMICAL COMPOUNDS

The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.

CHEMICAL COMPOUNDS

The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.

CHEMICAL COMPOUNDS

The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.

Non-nucleoside reverse transcriptase inhibitors

The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein A is A1, A2, A3 or A4 and R1, R2, R3, R4a, R4b, R5, R6, Ar, X1, X2, X4, X4 and X5 are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds.

Non-nucleoside reverse transcriptase inhibitors

Compounds of formula I, wherein R1, R2, R3, R4, Ra, X, X1, and Y are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.

Non-nucleoside reverse transcriptase inhibitors

Compounds of formula I, wherein R1, R2, R3, R4, R5, X, Y, and Ar are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.